In a prospective single arm study, Lumenis IPL with OPT™ combined with MGX reduced the number and severity of symptoms and signs of dry eye disease in subjects with moderate to severe MGD.
Yang et al. (2021): Treatment of contact lens related dry eye with intense pulsed light
In a prospective paired-eye study of patients wearing contact lenses and experiencing contact lens related dry eye, eyes treated with Lumenis IPL with OPTTM improved in signs and symptoms of dry eye disease (DED).
Light After the Storm: A Hopeful Look Ahead for Dry Eye Disease
Dr. Laura M. Periman explains the multifactorial complexity of dry eye disease—and how OptiLight is helping the future look bright.
Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye
Researchers found that 20 tear cytokines decreased significantly after IPL treatment, illustrating how IPL suppresses DED’s vicious cycle of inflammation.
Not All IPL Devices Are Created Equal
Blog PostsDry Eye Not All IPL Devices Are Created Equal December 5, 2023 Cory J. Lappin, OD, MS, FAAO Phoenix Eye Care and the Dry Eye Center of Arizona Dr.
Toyos et al. (2022) Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study
The US FDA approval for Lumenis IPL with OPT™ for management of DED was based on this recent clinical study. In this perspective, multi-center, double-blinded, randomized controlled study, Lumenis IPL with OPT™ combined with MGX significantly improved signs of DED due to MGD in patients with moderate to severe symptoms.
SLT + YAG
From the first SLT laser to the first argon laser photocoagulator to the revolutionary dual-path SLT+YAG laser. We have never stopped moving forward, with Digital Duet / Trio we are continuing a long tradition of offering superior products today and pioneering the next evolution of products for tomorrow.
Itay Mayer, VP and Managing Director of Lumenis Vision, shares exciting product updates about OptiLight 2.0 and insights into Lumenis’ consumer campaign at VEE 2023
Itay Mayer, Vice President and Managing Director of Lumenis Vision, caught up with Optometry Times® to share an update on the company and its products, which was showcased during the 2023 Vision Expo East meeting in New York, New York.
Smart Selecta Trio
The Lumenis Selecta® Trio™ represents the next generation of multi-modality products, offering retinal, cataract and advanced glaucoma therapies in a single platform. The unit’s integrated design, enhanced optics system and advanced laser cavity make the Trio one of the highest performing laser products in the market – maximum flexibility with minimum footprint.
Vision One
Product Highlights Modular and upgradable – Ability to upgrade the system at any time by a adding wavelengths as a scanner User friendly design – Touch screen and remote keypad, Dual Port for efficient setup of alternate delivery devices, advance memory settings SureSpot™ Optics Technology – Sharply defined and evenly distributed power on the retinaList